You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
At Lundbeck UK we believe that improving patient care can be achieved through collaborative working with the NHS. The Associated Board of the Pharmaceutical Industry (ABPI) Code of Practice defines ‘Collaborative Working with Organisations’ as initiatives which:
Collaborative working is usually between one or more pharmaceutical companies, healthcare organisations or other organisations. Joint working is a form of collaborative between one or more Pharmaceutical companies, the NHS and other organisations which is patient centred and always benefits patients.
Our complete focus on the central nervous system (CNS) has led us to be an organisation that understands the healthcare systems and service models in this sector well beyond just the pharmacological aspects of healthcare. This enables us to support a holistic, whole pathway approach to improving the care of patients with brain disease and supporting the NHS to improve patient outcomes and achieve savings across the health economy.
Our expertise in mental health and our investment in tools and resources allows us to help our customers deliver improved patient outcomes and achieve objectives through support such as:
We believe that projects like these can lead to benefits for patients, improve access to relevant healthcare services and support better healthcare outcomes.
We are dedicated to improving access to brain health in accordance with WHO.
We are patient-driven, courageous, ambitious, passionate and responsible.
Our heritage and success have provided us with a strong global network.
UK-NOTPR-0537 | April 2022